In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $RARE Ultragenyx and its Phase Three Orbit and Cosmic trials for setrusumab in osteogenesis imperfecta. We examine bone mineral density gains, failed fracture reduction endpoints, interim analysis results, the forty two percent stock drop, and alleged misleading statements about clinical trial confidence. This deep dive is for biotech investors, healthcare traders, and anyone following rare disease drug development, FDA pathways, and securities litigation news.

Visit ZLK.com for more info.

Add our WhatsApp Channel.